Astrazeneca Plc $AZN Stock Position Reduced by Gabelli Funds LLC

Gabelli Funds LLC lessened its stake in Astrazeneca Plc (NYSE:AZN) by 69.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 19,100 shares of the company’s stock after selling 43,900 shares during the quarter. Gabelli Funds LLC’s holdings in Astrazeneca were worth $3,767,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Triumph Capital Management acquired a new stake in shares of Astrazeneca during the 3rd quarter valued at $25,000. MV Capital Management Inc. purchased a new stake in shares of Astrazeneca during the fourth quarter worth $26,000. Mascoma Wealth Management LLC purchased a new stake in shares of Astrazeneca during the first quarter worth $26,000. Bangor Savings Bank boosted its position in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC purchased a new position in Astrazeneca in the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research reports. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. HSBC cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Stock Up 1.6%

Shares of Astrazeneca stock opened at $172.41 on Wednesday. The stock has a market capitalization of $267.39 billion, a P/E ratio of 25.77, a PEG ratio of 1.38 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a 50 day moving average price of $180.02 and a two-hundred day moving average price of $187.95. Astrazeneca Plc has a 12-month low of $145.14 and a 12-month high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.95% and a net margin of 17.02%.The company had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. During the same quarter last year, the company posted $2.17 earnings per share. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. Equities analysts expect that Astrazeneca Plc will post 10.22 earnings per share for the current year.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Quarterly earnings beat expectations: AstraZeneca reported adjusted EPS of $2.63, above the $2.50 consensus estimate. Revenue rose 6.4% year over year to $15.38 billion, narrowly missing expectations, while oncology, cardiovascular and rare-disease medicines helped offset generic competition. AstraZeneca beats second-quarter profit expectations, holds outlook
• Positive Sentiment: Full-year outlook maintained: Management backed its 2026 forecasts, helping reassure investors that strength in key growth franchises can offset weaker sales, product exclusivity pressure and challenges in China. AstraZeneca earnings beat forecasts despite slight revenue miss
• Positive Sentiment: Some analysts remain constructive: Citi raised its price target to 17,800 pence, citing AstraZeneca’s potential drug pipeline and long-term revenue ambitions. AstraZeneca’s drug pipeline is splitting opinion among City analysts
• Neutral Sentiment: Pricing strategy is changing: An executive said AstraZeneca is adjusting pricing for new U.S. drug launches in response to the Trump administration’s most-favoured-nation policy. The changes could affect future pricing and margins, but the financial impact remains uncertain. AstraZeneca drug prices evolving in response to Trump policy
• Negative Sentiment: Pipeline setback adds pressure: Rare-disease drug Ultomiris failed to meet the main goal in a late-stage trial involving a blood-vessel complication after stem-cell transplantation, renewing concerns about AstraZeneca’s longer-term growth pipeline. AstraZeneca’s rare disease drug misses main goal in late-stage trial
• Negative Sentiment: Analyst views are divided: Deutsche Bank reiterated a “sell” rating with an 11,500-pence valuation, highlighting uncertainty around pipeline execution and future growth. In addition, Pomerantz LLP announced an investigation into potential investor claims, which could create legal and reputational overhang. Pomerantz investor alert regarding AstraZeneca

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.